Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL897350 | 0.91 | F10 (0.50) | F10LMNASCN9AGPR55KMT2A | |
| SCHEMBL890755 | 0.91 | F10 (0.46) | F10LMNASCN9AGPR55KMT2A | |
| SCHEMBL890838 | 0.91 | F10 (0.48) | F10LMNASCN9AGPR55KMT2A | |
| SCHEMBL890596 | 0.80 | F10 (0.48) | F10LMNASCN9AGPR55KMT2A | |
| SCHEMBL890746 | 0.79 | F10 (0.60) | F10LMNASCN9A | |
| SCHEMBL897349 | 0.72 | F10 (0.62) | F10LMNAALDH1A1 | |
| SCHEMBL890914 | 0.72 | GPR55 (0.47) | F10LMNASCN9AGPR55KMT2A | |
| SCHEMBL7681921 | 0.71 | F10 (0.48) | F10GPR55 | |
| SCHEMBL890850 | 0.71 | F10 (0.51) | F10LMNASCN9AGPR55KMT2A | |
| SCHEMBL890607 | 0.71 | F10 (0.49) | F10LMNAGPR55KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10179124-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2018-02-08 | — | — | US | disclosed |
| US-9629831-B2 | Benzamides and related inhibitors of factor XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160317511-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9108922-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140377247-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-8518977-B2 | Benzamides and related inhibitors of factor XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130172310-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. | 2013-07-04 | — | — | US | disclosed |
| US-20120083602-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. | 2012-04-05 | — | — | US | disclosed |
| US-8063036-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-6835739-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-12-28 | — | — | US | disclosed |
| US-20040097561-A1 | For therapy of thrombosis | MILLENNIUM PHARMACEUTICALS, INC. | 2004-05-20 | — | — | US | disclosed |
| US-20030162690-A1 | Bood anticoagulant | COR THERAPEUTICS, INC. | 2003-08-28 | — | — | US | disclosed |
| EP-1259485-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-1216228-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| US-6376515-B2 | DERIVATIVES OF A 2-((4-AMIDINYLPHENYL)-CARBONYLAMINO-1,2-PHENYLENE)-CARBONYLAMINO-) PYRIDINE; POTENT AND HIGHLY SELECTIVE ANTICOAGULANTS; BIOAVAILABILITY AND/OR SOLUBILITY; PREVENTION AND TREATMENT OF THROMBOSIS AND COAGULATION | COR THERAPEUTICS, INC. | 2002-04-23 | — | — | US | disclosed |
| US-20020002183-A1 | Derivatives of a 2-((4-amidinylphenyl)-carbonylamino-1,2-phenylene)-carbonylamino-)pyridine; potent and highly selective anticoagulants; bioavailability and/or solubility; prevention and treatment of thrombosis and coagulation | MILLENNIUM PHARMACEUTICALS, INC. | 2002-01-03 | — | — | US | disclosed |
| WO-2001064642-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001064643-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001019788-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160317511-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | F10 13/4885LMNA 218/4885SCN9A 533/4885 |
| US-20040097561-A1 | For therapy of thrombosis | F2, F12, TFPI | F10 21/4885LMNA 358/4885SCN9A 1505/4885 |
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | F10 13/4885LMNA 218/4885SCN9A 533/4885 |
| US-20140377247-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | F10 13/4885LMNA 218/4885SCN9A 533/4885 |
| US-20120083602-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | F10 13/4885LMNA 218/4885SCN9A 533/4885 |
| US-20130172310-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | F10 13/4885LMNA 218/4885SCN9A 533/4885 |
| US-20020002183-A1 | Derivatives of a 2-((4-amidinylphenyl)-carbonylamino-1,2-phenylene)-carbonylamino-)pyridine; potent and highly selective anticoagulants; bioavailability and/or solubility; prevention and treatment of thrombosis and coagulation | F2, F12, PLAT | F10 14/4885LMNA 187/4885SCN9A 2260/4885 |
| US-10179124-B2 | Benzamides and related inhibitors of factor Xa | TFPI, F12, TFPI2 | F10 13/4885LMNA 218/4885SCN9A 533/4885 |
| US-20030162690-A1 | Bood anticoagulant | F2, SERPINC1, HABP2 | F10 18/4885LMNA 220/4885SCN9A 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.